A new national survey from Imagine360, a leading alternative health plan for self-funded employers, reveals a rising healthcare affordability crisis with 1 in 3 insured Americans saying they’re losing sleep over the cost of care. As employer-sponsored healthcare costs climb to record highs, nearly half (44%) of survey respondents are […]
ARTICLES
New AI Technology to Speed Drug Development
University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines. UVA’s Nikolay V. Dokholyan, PhD, and colleagues have developed a suite of artificial intelligence-powered tools, called YuelDesign, YuelPocket and YuelBond, that work together to […]
Narcolepsy Network Announces Addition of Two New Board Members
Narcolepsy Network, a national non-profit organization for people living with narcolepsy and idiopathic hypersomnia (IH), is proud to announce the appointment of Desireé Gorbea-Finalet and Mike Heil to its Board of Directors. Both new members live with narcolepsy and will bring fresh perspectives and deep advocacy experience to the organization as it prepares to […]
NightWare Announce Strategic Investment Partnership
NightWare, Inc. and Exit 156 Capital announced a strategic investment by Exit 156 in NightWare’s ongoing Series C financing. NightWare is the maker of the only FDA-cleared prescription digital therapeutic indicated for nightmare disorder in adults with post-traumatic stress disorder (PTSD). The partnership unites a Minneapolis-based growth-stage digital health company […]
Dreem Health Joins Amazon’s Health Benefits Connector As The Platform’s First Sleep Health Provider
Dreem Health, a leading virtual sleep clinic managed by Sunrise Group, has become the first sleep care service to join Amazon’s Health Benefits Connector. Amazon customers eligible for insurance-covered sleep services can discover and enroll in Dreem Health’s personalized care when browsing for healthcare services. More than 70 million Americans live with sleep […]
ProSomnus Receives FDA Class II Clearance for RPMO₂ OSA Device
ProSomnus Sleep Technologies announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂ OSA Device under the product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765). The RPMO2 OSA Device is the first theragnostic device for sleep medicine, incorporating both precision […]
Mount Sinai Develops AI Tool to Predict Cardiovascular Risk in OSA
Mount Sinai researchers have created an analytic tool using machine learning that can predict cardiovascular disease risk in millions of patients with obstructive sleep apnea, a serious sleep disorder, according to findings recently published in Communications Medicine. The team said their study is the first to provide estimates of whether […]
American Academy of Sleep Medicine launches Full PSG Autoscoring Certification Program
The American Academy of Sleep Medicine has introduced the Full PSG Autoscoring Certification Program, a new initiative that independently evaluates and certifies autoscoring software that interprets adult sleep stages and events from polysomnography data. The Full PSG Autoscoring Certification Program represents a significant expansion of the AASM’s earlier pilot initiative, which launched […]
Clinical Trial of Early Morning Shift Workers Shows Promise of New Drug for Reducing Excessive Sleepiness
Many more people work very early morning shifts than overnight ones, and a large proportion struggle with excessive sleepiness from shift work disorder, leading to problems with focus, performance and safety. A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early […]
Apnimed Secures $150M to Advance AD109 Toward Launch
Apnimed, Inc., announced that it has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners (“HCRx”). The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed’s lead product candidate, AD109, if approved by the […]













